Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

Access to healthcare

MSF response to Gilead announcement on inclusion of hepatitis C drug GS-5816 in voluntary licence

Editor's pick
Médecins Sans Frontières press release
27 January 2015
New & experimental hepatitis C treatment

Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent

Editor's pick
Gilead press release
27 January 2015
Access to healthcare

How India's Patent Office Destroyed Gilead's Global Game Plan

Editor's pick
Bloomberg Businessweek
19 January 2015
New & experimental hepatitis C treatment

Merck speeds up drug-submission plans for hep C, lung cancer

Editor's pick
Reuters
13 January 2015
The search for a cure

New open-access journal in the rapidly developing field of virus eradication

Editor's pick
Mediscript
23 December 2014
New & experimental hepatitis C treatment

US FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeks

Editor's pick
Reuters
20 December 2014
New & experimental hepatitis C treatment

Daclatasvir for hepatitis C: added benefit not proven

Editor's pick
German Institute for Quality and Efficiency in Health Care (IQWiG)
11 December 2014
New & experimental hepatitis C treatment

FDA declines to approve Bristol-Myers hepatitis drug

Editor's pick
Reuters
27 November 2014
Hepatitis C transmission & prevention

"Promising" results in Oxford trials of Hepatitis C vaccine

Editor's pick
Cherwell
26 November 2014
New & experimental hepatitis C treatment

CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Editor's pick
AbbVie press release
21 November 2014
Hepatitis C treatment

NHS asks Nice to delay ground-breaking hepatitis C drug

Editor's pick
Channel 4 News (blog)
19 November 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir)

Editor's pick
Gilead press release
19 November 2014
Hepatitis C treatment

New HCV drugs pass muster in real world

Editor's pick
MedPage Today
11 November 2014
New & experimental hepatitis C treatment

New pill that can cure hepatitis C approved for patients in Scotland

Editor's pick
STV
11 November 2014
New & experimental hepatitis C treatment

Merck’s four-week treatment for hepatitis C misses the mark

Editor's pick
Wall Street Journal
11 November 2014
New & experimental hepatitis C treatment

Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients

Editor's pick
Bristol-Myers Squibb press release
10 November 2014
New & experimental hepatitis C treatment

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

Editor's pick
Achillion press release
10 November 2014
New & experimental hepatitis C treatment

Merck's Four-Week Hepatitis C Regimen Fails to Top Gilead

Editor's pick
Bloomberg
10 November 2014
Pharmaceutical industry

Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

Editor's pick
Wall Street Journal
5 November 2014
Hepatitis C treatment

Bristol-Myers Squibb announces HCV global access plans

Editor's pick
Bristol-Myers Squibb press release
3 November 2014
New & experimental hepatitis C treatment

IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

Editor's pick
HIVandHepatitis.com
16 October 2014
New & experimental hepatitis C treatment

Fair Pricing Coalition Urges a Uniform Price for Curative Hepatitis C Treatment

Editor's pick
Fair Pricing Coalition
15 October 2014
Pharmaceutical industry

If AbbVie Discounts its Hep C Drug, Would Pricing Reach a Tipping Point?

Editor's pick
Wall Street Journal
15 October 2014